SEC Form 4 · accession 0001651844-16-000014
NYMOX PHARMACEUTICAL CORP · NYMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James George Robinson
Director
Period of report
Mar 28, 2016
Accepted (ET)
Apr 1, 2016 · 5:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001018735
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 28, 2016 | P | 3,500 | $2.27 | A | 2,701,050 | D | |
| Common Stock | Mar 31, 2016 | P | 4,500 | $2.45 | A | 2,705,550 | D | |
| Common Stock | Mar 31, 2016 | P | 4,500 | $2.44 | A | 2,710,050 | D | |
| Common Stock | Mar 31, 2016 | P | 4,500 | $2.40 | A | 2,714,550 | D | |
| Common Stock | Apr 1, 2016 | P | 3,500 | $2.44 | A | 2,718,050 | D | |
| Common Stock | holding | — | — | — | 45,050 | I | Trust | |
| Common Stock | holding | — | — | — | 45,050 | I | Trust | |
| Common Stock | holding | — | — | — | 45,050 | I | Trust | |
| Common Stock | holding | — | — | — | 45,050 | I | Trust | |
| Common Stock | holding | — | — | — | 45,050 | I | Trust |
Table II — derivative securities
No Table II lines on this filing.